European Psychiatry - Volume 33 - March 2016

690 / 812

S686 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
3 Parc de Salut Mar, INAD, CSMA, Santa Coloma de Gramanet, Spain
∗ Corresponding author.
Introduction Extrapyramidal symptoms are well known as side
effects in therapy with antipsychotics. Explore this side effects is
mandatory because they normally are a cause of treatment discon-
tinuation or assess a change in medication. Some studies notice
how long acting injectable antipsychotic cause less extrapyramidal
symptoms than oral treatment, others does not find differences.
Objective The aim of this study is to analyze the extrapyramidal
symptoms presented on a group of patients treated with aripipra-
zole long acting injectable (ALAI) follow-up in a mental health care
center.
Methods Descriptive study of a group of patients treated with
ALAI. To assess the possible extrapyramidal symptoms due to treat-
ment we have used the Simpson-Angus Scale (SAS). The follow up
was 3 months after initiation of treatment.
Results Six patients were included in the study, 2 women (33.3%)
and 4 men (66.7%). The mean age of the sample was 37 years old.
The different diagnoses of the group were 4 patients with psy-
chotic disorder (66.7%; 2 schizophrenia, 1 schizoaffective disorder
and 1 delusional chronic disorder) and the other 2 had an affective
disorder (33.3%; both bipolar disorder). The average score for the
SAS was 1.2 meaning normal results and therefore no significant
extrapyramidal symptoms.
Conclusions In our sample the average of the results obtained by
applying the SAS is considered within normal limits. In our case as
to extrapyramidal effects ALAI treatment has been well tolerated.
A larger sample would be needed to obtain more reliable results.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1054
Neuroleptic prescriptions sequences
analysis in relation to cardiovascular
medication and death occurrence in
Poland
P. Zagozdzon ∗, B. Goyke , P. Dorozynski
1 Medical University of Gdansk, Department of Hygiene and
Epidemiology, Gdansk, Poland
2 National Health Fund, Department of Monitoring and Analysis,
Gdansk, Poland
3 Gdansk University of Technology, Faculty of Electronics,
Telecommunications and Informatics, Gdansk, Poland
∗ Corresponding author.
Introduction The potential role of antipsychotic treatment in
increasing cardiovascular risk and in explaining the increasedmor-
tality due to somatic disorders is still debated. The aim of this study
was to assess the sequences of atypical and atypical neuroleptic
prescriptions in relation to cardiovascular medication and death
occurrence.
Methods We conducted a retrospective longitudinal analysis
involving 84,881 patients who had drug insurance benefits in
Pomeranian voivodship and who were receiving a typical or atyp-
ical antipsychotic medication between 2008 and 2012. Data on
deaths have been collected from National Death Registry. The
sequence creation was performed according to algorithm that
iterates over neuroleptic prescriptions in chronological order and
appends them to the end of patient’s prescriptions sequence.
Patients were also assigned to cardiovascular groups depending on
the use of cardiovascular or diabetic medications before, simulta-
neously or after the treatment with neuroleptics.
Results There were 1,095,518 neuroleptic prescriptions and
16,010 deaths among antipsychotic users in analyzed period.
The most prevalent sequence was consisting of typical neurolep-
tics. Less frequent were sequenced with use of both typical and
atypical drugs or only atypical medications. The least frequent were
sequenced with clozapine or clozapine with other neuroleptics.
The highest occurrence of death and occurrence of cardiovascu-
lar drug after introducing antipsychotic treatment was observed
for clozapine. There was lower occurrence of death in atypical neu-
roleptic sequence compared to typical drug sequence but similar
prevalence of cardiovascular drugs.
Conclusion These results suggest that conventional antipsychotic
medications are associated with increased risk of death compared
to atypical drugs.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1055
Indication of depot antipsychotic
treatment in the view of slovak
psychiatrists
M. Zelman
Psychiatricka Nemocnica, Hronovce, Slovakia
With the increasing number of atypical antipsychotics in depot
form, there emerges question about plus and cons of their use in
schizophrenia patients. We focused on the opinion of Slovak psy-
chiatrists about use of this treatment in some specific situations
of schizophrenia treatment. Research was realized via question-
naire on psychiatrists (n = 47) from ambulant and hospital care,
during one conference in June 2015. First part of the questionnaire
was focused on the preference of oral or depot form of antipsy-
chotic treatment. Depot form would be indicated by psychiatrists
(in more than 89%) when low compliance, anosognosia or frequent
episodes. On the contrary, oral antipsychotic treatment is preferred
in young patients or employed patients. The type of symptoms (e.g.
positive, negative) has relatively small impact on the preference
of treatment, where the preferences of each type were the lowest
(fewer than 36%). According to the opinion of psychiatrists, depot
antipsychotic treatment is not suitable in first episode of disorder
(according to 81% of respondents), otherwise in second or third
episode it would not be chosen by 6% of asked psychiatrists.
From the aspects of the choice between atypical or typical depot,
atypical antipsychotics in depot formwere favored when presence
of adverse reactions (80%), occurrence of negative symptoms (65%)
and short duration of disorder (58%). Typical depot was preferred
by psychiatrists in patients with chronic states.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1056
Asenapine modulates nitric oxide
release and calcium movements in
cardyomyoblasts
P. Zeppegno∗, C. Gramaglia , E. Gattoni , S. Gili , E. Gambaro ,
E. Di Tullio , M.C. Rizza , S. Farruggio , L. Camillo , D. Mary ,
G. Vacca , E. Grossini
University of Eastern Piedmont, Traslational Medicine, Novara, Italy
∗ Corresponding author.
Objective To examine the effects of asenapine on NO release and
Ca2+ transients in H9 C2 , which were either subjected to peroxida-
tion or not.
Materials and methods H9C2 were treated with asenapine alone
or in presence of intracellular kinases blockers, serotoninergic and
dopaminergic antagonists, and voltage Ca2+ channels inhibitors.
Experiments were also performed in H9C 2 treated with hydrogen
peroxide. NO release and intracellular Ca2+ weremeasured through
specific probes.